Page 113 - 南京医科大学学报自然科学版
P. 113

第43卷第10期                   汪徐春,孙玉洁. 增强子调控异常与恶性肿瘤的关系研究进展[J].
                 2023年10月                  南京医科大学学报(自然科学版),2023,43(10):1432-1440,1478                   ·1439 ·


                    Biol,2020,17(11):1550-1559                         hijacking activates GFI1 family oncogenes in medullo⁃
               [20] LI W B,NOTANI D,MA Q,et al. Functional roles of en⁃  blastoma[J]. Nature,2014,511(7510):428-434
                    hancer RNAs for oestrogen⁃dependent transcriptional acti⁃  [34] MONTEFIORI L E,BENDIG S,GU Z H,et al. Enhancer
                    vation[J]. Nature,2013,498(7455):516-520           hijacking drives oncogenic BCL11B expression in lineage⁃
               [21] BOSSÉ Y,AMOS C I. A decade of GWAS results in lung  ambiguous stem cell leukemia[J]. Cancer Discov,2021,
                    cancer[J]. Cancer Epidemiol Biomarkers Prev,2018,27  11(11):2846-2867
                    (4):363-379                                  [35] GALA K,LI Q,SINHA A,et al. KMT2C mediates the es⁃
               [22] HU Z B,WU C,SHI Y Y,et al. A genome⁃wide associa⁃  trogen dependence of breast cancer through regulation of
                    tion study identifies two new lung cancer susceptibility lo⁃  ERα enhancer function[J]. Oncogene,2018,37(34):
                    ci at 13q12.12 and 22q12.2 in Han Chinese[J]. Nat Gen⁃  4692-4710
                    et,2011,43(8):792-796                        [36] LV S,WEN H,SHAN X,et al. Loss of KMT2D induces
               [23] XU J F,MO Z N,YE D W,et al. Genome⁃wide associa⁃   prostate cancer ROS⁃mediated DNA damage by suppress⁃
                    tion study in Chinese men identifies two new prostate can⁃  ing the enhancer activity and DNA binding of antioxidant
                    cer risk loci at 9q31.2 and 19q13.4[J]. Nat Genet,2012,  transcription factor FOXO3[J]. Epigenetics,2019,14
                    44(11):1231-1235                                  (12):1194-1208
               [24] WANG X C,CHENG H,YANG Y,et al. The enhancer  [37] MAITITUOHETI M,KEUNG E Z,TANG M,et al. En⁃
                    rare germline variation rs548071605 contributes to lung  hancer reprogramming confers dependence on glycolysis
                    cancer development[J]. Hum Mutat,2022,43(2):200-   and IGF signaling in KMT2D mutant melanoma[J]. Cell
                    214                                                Rep,2020,33(3):108293
               [25] GUAN W,YANG N,ZUO X,et al. Heritable variants in  [38] GAO S,CHEN S,HAN D,et al. Chromatin binding of
                    the chromosome 1q22 locus increase gastric cancer risk  FOXA1 is promoted by LSD1⁃mediated demethylation in
                    via altered chromatin looping and increased UBAP2L ex⁃  prostate cancer[J]. Nat Genet,2020,52(10):1011-1017
                    pression[J]. Mol Cancer Res,2021,19(12):1992-2002  [39] GOZDECKA M,MEDURI E,MAZAN M,et al. UTX⁃me⁃
               [26] TIAN P,ZHONG M J,WEI G H. Mechanistic insights in⁃  diated enhancer and chromatin remodeling suppresses
                    to genetic susceptibility to prostate cancer[J]. Cancer  myeloid leukemogenesis through noncatalytic inverse
                    Lett,2021,522:155-163                              regulation of ETS and GATA programs[J]. Nat Genet,
               [27] SHAO L P,ZUO X L,YANG Y,et al. The inherited varia⁃  2018,50(6):883-894
                    tions of a p53 ⁃ responsive enhancer in 13q12.12 confer  [40] D’OTO A,FANG J,JIN H,et al. KDM6B promotes acti⁃
                    lung cancer risk by attenuating TNFRSF19 expression[J].  vation of the oncogenic CDK4/6 ⁃ pRB ⁃ E2F pathway by
                    Genome Biol,2019,20(1):103                         maintaining enhancer activity in MYCN⁃amplified neuro⁃
               [28] HUA J T,AHMED M,GUO H Y,et al. Risk SNP⁃mediated   blastoma[J]. Nat Commun,2021,12(1):7204
                    promoter⁃enhancerswitchingdrivesprostatecancer through  [41] MAN N,MAS G,KARL D L,et al. p300 suppresses the
                    lncRNA PCAT19[J]. Cell,2018,174(3):564-575         transition of myelodysplastic syndromes to acute myeloid
               [29] GAO P,XIA J H,SIPEKY C,et al. Biology and clinical  leukemia[J]. JCI Insight,2021,6(19):e138478
                    implications of the 19q13 aggressive prostate cancer sus⁃  [42] MANSOUR M R,ABRAHAM B J,ANDERS L,et al. An
                    ceptibility locus[J]. Cell,2018,174(3):576-589     oncogenic super⁃enhancer formed through somatic muta⁃
               [30] OLDRIDGE D A,WOOD A C,WEICHERT⁃LEAHEY N,           tion of a noncoding intergenic element[J]. Science,2014,

                    et al. Genetic predisposition to neuroblastoma mediated  346(6215):1373-1377
                    by a LMO1 super ⁃ enhancer polymorphism[J]. Nature,  [43] SAGHAFINIA S,MINA M,RIGGI N,et al. Pan⁃cancer
                    2015,528(7582):418-421                             landscape of aberrant DNA methylation across human tu⁃
               [31] HNISZ D,WEINTRAUB A S,DAY D S,et al. Activation    mors[J]. Cell Rep,2018,25(4):1066-1080
                    of proto⁃oncogenes by disruption of chromosome neighbor⁃  [44] 唐思敏,邓雪婷,李全朋,等. 胆管癌的表观遗传学进展
                    hoods[J]. Science,2016,351(6280):1454-1458        [J]. 南京医科大学学报(自然科学版),2018,38(9):
               [32] ZHANG X Y,CHOI P S,FRANCIS J M,et al. Somatic su⁃  1322-1325
                    perenhancer duplications and hotspot mutations lead to  [45] BELL R E,GOLAN T,SHEINBOIM D,et al. Enhancer
                    oncogenic activation of the KLF5 transcription factor[J].  methylation dynamics contribute to cancer plasticity and
                    Cancer Discov,2018,8(1):108-125                    patient mortality[J]. Genome Res,2016,26(5):601-611
               [33] NORTHCOTT P A,LEE C,ZICHNER T,et al. Enhancer  [46] ARAN D,SABATO S,HELLMAN A. DNA methylation of
   108   109   110   111   112   113   114   115   116   117   118